Two posters demonstrated that povorcitinib showed durable 54-week efficacy and a favorable safety profile in moderate to severe HS, including patients previously on anti-TNF therapy. This content was ...
Clinicians need to adjust their diagnostic lens and counseling strategies in patients with skin of color, explained Joseph Lam, MD. This content was developed independently and is not endorsed by the ...
Experts at the 2026 AAD Annual Meeting noted that, together, PCP support, community outreach, and teledermatology help reduce care gaps. This content was developed independently and is not endorsed by ...
Linda Stein Gold, MD, shares efficacy and safety findings from the ICONIC-ADVANCE studies in moderate to severe psoriasis. This content was developed independently and is not endorsed by the American ...
Experts at the 2026 AAD Annual Meeting explained that teledermatology helps dermatologists manage their workload and expand patient access beyond traditional in-person care. Elizabeth Jones, MD, FAAD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results